ugn-103
Generic: mitomycin
ugn-103: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| UroGen Pharma Ltd. (URGN) | Phase 3 |
Clinical Trials (1)
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low-grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate-risk (IR) of Recurrence
Frequently asked questions
Who is developing ugn-103?
ugn-103 is being developed by UroGen Pharma Ltd..
How many clinical trials involve ugn-103?
BioSniper tracks 1 clinical trial involving ugn-103.
Get deeper analysis on ugn-103
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis